公开(公告)号：US06613535B1

公开(公告)日：2003-09-02

申请号：US07968553

申请日：1992-10-29

申请人： Joachim Albrecht ,  Frank Hulstaert ,  Rosette Becker

发明人： Joachim Albrecht ,  Frank Hulstaert ,  Rosette Becker

IPC分类号： G01N3353

CPC分类号： G01N33/5094 ,  G01N15/14 ,  G01N33/56977 ,  Y10S435/967 ,  Y10S435/968 ,  Y10S436/805 ,  Y10S436/811 ,  Y10T436/10 ,  Y10T436/101666 ,  Y10T436/106664

摘要： This invention relates to a method for establishing and using a decision marker by which positive samples can be discriminated from negative samples. The method employs the analysis of multiple samples from confirmed positive and negative samples. A fluorescence channel is selected so that the desired sensitivity and specificity are achieved. A microparticle having this fluorescence channel then is made and is used in conjunction with a fluorescence marker which is specific for the population of interest.

摘要翻译： 本发明涉及一种用于建立和使用决定标记的方法，通过该方法可以将正样本与负样本区分开来。 该方法采用从确认的阳性和阴性样本中分析多个样本。 选择荧光通道，使得实现所需的灵敏度和特异性。 然后制备具有该荧光通道的微粒，并与与感兴趣群体特异的荧光标记物结合使用。

公开(公告)号：US20070048281A1

公开(公告)日：2007-03-01

申请号：US11381408

申请日：2006-05-03

申请人： Geert Maertens ,  Erik Depla ,  Christina Stichele ,  Frank Hulstaert

发明人： Geert Maertens ,  Erik Depla ,  Christina Stichele ,  Frank Hulstaert

IPC分类号： A61K48/00 ,  A61K38/21 ,  A61K39/29

CPC分类号： C07K14/005 ,  A61K38/212 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55522 ,  C12N2770/24222 ,  C12N2770/24234 ,  A61K2300/00

摘要： The invention relates to therapy of HCV infection, and more particularly to combination therapy of HCV infection. The combination therapy comprises combination of a HCV E1 vaccine and an antiviral agent. In one aspect, the antiviral agent may be an interferon.

摘要翻译： 本发明涉及HCV感染的治疗，更具体地涉及HCV感染的联合治疗。 联合疗法包括HCV E1疫苗和抗病毒剂的组合。 一方面，抗病毒剂可以是干扰素。

公开(公告)号：US20050037018A1

公开(公告)日：2005-02-17

申请号：US10871704

申请日：2004-06-21

申请人： Geert Maertens ,  Erik Depla ,  Christina Stichele ,  Frank Hulstaert

发明人： Geert Maertens ,  Erik Depla ,  Christina Stichele ,  Frank Hulstaert

IPC分类号： A61K38/18 ,  A61K38/19 ,  C07K14/18 ,  A61K48/00 ,  A61K39/29

CPC分类号： C07K14/005 ,  A61K38/212 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55522 ,  C12N2770/24222 ,  C12N2770/24234 ,  A61K2300/00

摘要： The invention relates to therapy of HCV infection, and more particularly to combination therapy of HCV infection. The combination therapy comprises combination of a HCV E1 vaccine and an antiviral agent. In one aspect, the antiviral agent may be an interferon.

摘要翻译： 本发明涉及HCV感染的治疗，更具体地涉及HCV感染的联合治疗。 联合疗法包括HCV E1疫苗和抗病毒剂的组合。 一方面，抗病毒剂可以是干扰素。

公开(公告)号：US06670137B2

公开(公告)日：2003-12-30

申请号：US09892835

申请日：2001-06-27

申请人： Eugeen VanMechelen ,  Hugo Vanderstichele ,  Frank Hulstaert

发明人： Eugeen VanMechelen ,  Hugo Vanderstichele ,  Frank Hulstaert

IPC分类号： G01N3353

CPC分类号： G01N33/6896 ,  G01N2800/28 ,  G01N2800/2821 ,  G01N2800/2835

摘要： The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.